Faced with the worldwide shortage of organs, 1,2 patients are increasingly traveling abroad for a transplant. 3 Often there is limited donor information when they return which can pose management problems. One example is the lack of information about the donor human leukocyte antigen (HLA) type. In our practice, around 6% of all transplanted patients do not have adequate donor HLA information. If this kidney is subsequently lost, the lack of such information may be a concern in retransplantation. It is a common practice not to retransplant someone with a kidney that expresses mismatched antigens present on previously failed transplants, even in the absence of HLA-specific antibodies. It would not be possible to avoid such antigens if the initial donor HLA type were unknown.
Second, there is increasing interest in post-transplant immunological monitoring, 4 both donor-specific antibodies, 5 and cellular reactivity. 6 Having complete information on the donor HLA type would assist the performance and interpretation of such assays using surrogate cells or beads, if donor material is not available.
Third, many donors of current long-lived transplants were never tissue typed for class II and their class I typing was less precise.
Donor and recipient DNA are detectable in urine from kidney transplant recipients. 7 With the development of tissue typing techniques, requiring less DNA, we explored the possibility of obtaining retrospective HLA-type information on transplant donors from recipient urine. We believe this is the first demonstration that this can be done.
RESULTS
DNA was extracted from urine specimens from 34 stable renal transplant recipients, and 13 control individuals who were free of known renal pathology and who had not undergone renal transplantation. All eluates were subjected to HLA class I ( Figure 1 ) and II (online Supplementary Information) typing. The recipient's known HLA type (as identified from HLA typing of a whole-blood sample from the recipient) was subtracted from the HLA type determined from urinary DNA. HLA specificities not present in the recipient's pretransplant tissue type were assigned to the donor and results compared with donor HLA type known from pretransplant typing, to confirm the accuracy of the urinary HLA type.
Only 3 of the 34 urine samples failed to produce adequate DNA for tissue typing from 50 ml. Of these, two had been frozen before processing and one had been left overnight before DNA was isolated. 8 samples of data, representative of the 31 patients studied, are shown in Table 1 . Of these, one (patient 15) failed to generate an expected A33 and Cw16. Two expected alleles in patient 12 were not detected in the urine, but in each case this was in the context of a technical failure. Table 2 summarizes the mismatch data in all 31 patients. Patient 15 had undergone two transplants, from the first of which no donor details were available. No unexpected alleles were detected from the first kidney but the expected mismatches from the second graft were all identified.
Across all 31 patients, there were a total of 159 donor-recipient mismatches. Of these, 140 (88%) were detected from recipient's urine. Of the 19 (12%) that were not detected, the internal control reactions failed in all cases that were thus known to be technical failures. These are shaded in Table 2 . This gave a 'miss (false negative) rate' of 0% (that is, where the assay was believed to have been a technical success). A single false positive (HLA-DRw51 on patient 3) was detected, a rate of 0.8%. All 13 control specimens yielded expected tissue typing (data not shown).
DISCUSSION
This study demonstrates that it is possible to determine mismatched donor HLA specificities using DNA extracted from transplanted patients' urine. We missed no donor-recipient mismatched allele when the internal controls confirmed an assay was technically successful. Previous work has focused on methods for the extraction of urinary cell-free DNA [8] [9] [10] and its use to predict rejection without biopsy. 7, 10 The previous focus of urinary DNA extraction has been the detection of cancer markers, 11, 12 DNA polymorphisms, 13, 14 and infections. 15 Urinary DNA can be obtained from cell debris derived from the cells lining the urinary tracts, including tubules and bladder, 16 so-called 'transrenal DNA'. 17, 18 Donor-derived DNA constitutes a minor proportion (8.7%) of total urinary DNA, 9 but is still readily detectable. In a few cases, the assay failed on a fresh sample of 50 ml urine and we could not repeat the typing. However, the relative ease of obtaining fresh urine samples means that this should not be a limiting factor in practice. The test's simplicity means it is well within the capabilities of any routine histocompatibility laboratory. DNA can also be detected from frozen urine when stored appropriately. 19 The use of this technique should help in the maintenance of an accurate patient sensitization history and may also aid post-transplant monitoring.
MATERIALS AND METHODS Participants
Ethical approval was obtained from the Hammersmith Hospital Research Ethics Committee. Samples were collected after informed consent was granted.
A total of 34 transplant patients with stable creatinine levels (o10% increase) for 41-year following transplantation were recruited from the Hammersmith Hospital clinic in 2006. The control group comprised 13 individuals with no history of renal pathology or renal transplantation. We excluded infection in that none had positive urine culture or elevated serum C-reactive protein at the time of sample collection.
DNA extraction
DNA extraction from fresh urine sample. Fresh, early morning urine samples (50 ml) were centrifuged (4000 r.p.m., 30 min). DNA No of expected  mismatches  1  3  27  44  2  5  4  11  52  53  7  8  11  11  2  3 3  5 8  1 0  1 4  5 2  5  5  6  3  6 8  5 3  4  5 1   a   4  3  4  3  7  7  7  2  5  5  5  0  0  6  6 0  1 0  2  2  7  3  27  2  3  3  8  24  68  51  12  15  14  51  5  9  9  9  9  3  38  7  12  4  53  6 7  25  24  29  39  44  16  7  7  5  7  26  1  2  37  5  5  15  51  6  3  8  27  2  26  27  44  1  16  1  7  53  5  5  10  28  23  8  2  3  3  29  7  4  0  2  30  3  68  5  1  5  4  5  31  8  50  2  3  3  Total  141  159 The was extracted from the pellet using QIAamp Viral Mini Kit (Qiagen, Crawley, UK). (The constituents of buffers AVL, AW1, AW2 and AVE have not been disclosed by the manufacturer.) Briefly, the pellet and 250 ml supernatant were pulse-vortexed with four volumes of AVL/RNA carrier buffer (1 ml of buffer AVL to one tube lyophilized carrier RNA). Following incubation (room temperature, 10 min), an equal volume of 100% ethanol was added and the sample pulsevortexed. The mixture was applied to the QIAamp Spin Column and centrifuged. The eluate was discarded. Buffer AW1 (500 ml) was added to the column and centrifuged at 8000 r.p.m. (1 min). Next, 500 ml buffer AW2 was added and centrifuged (14,000 r.p.m., 3 min). DNA was eluted using five aliquots of 40 ml AVE buffer by spinning (8000 r.p.m., 1 min), after incubation at room temperature (1 min). DNA extraction from whole blood. Genomic DNA was isolated from whole blood using the Nucleon Genomic DNA Extraction Kit (Nucleon Biosciences, Manchester, UK) according to manufacturer's protocol. EDTA-whole blood (3 ml) was mixed with Reagent A (17 ml) (10 mM Tris-HCl, 320 mM sucrose, 5 mM MgCl 2 , 1%Triton X-100, pH 8.0) and centrifuged (1300 g, 5 min). The supernatant was discarded and 2 ml reagent B (400 mM Tris-HCl, pH 8.0, 60 mM EDTA, 150 mM NaCl, 1% SDS) added. Afterward 500 ml 5 M sodium perchlorate and 2 ml chloroform were added sequentially and the suspension was centrifuged (1300 g, 1 min). After centrifugation, 200 ml Nucleon Silica Suspension (Nucleon Biosciences) was added to the aqueous layer and the sample centrifuged (1300 g, 1 min). Finally, the DNA was precipitated in ethanol, dissolved in water and adjusted to 30-100 mg/ml. If a reaction failed to amplify a PCR product from its internal control, the sample was repeated if enough DNA was still available. Otherwise, it was classified as a 'failed' reaction.
